TuHURA Biosciences, Inc.
TAMPA, FL · Founded 2023 · CIK 0001252142 · Biotech · Public
Engineered probiotics and microbial therapeutics using proprietary strain development and formulation
tuhurabio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $21M
- 7 Form D · Dec 2023
- 34 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $20,000,000 | |
| Private capital raised | Form D · SEC | $1,757,214 | |
| Private capital raised | Form D · SEC | $495,000 | |
| Private capital raised | Form D · SEC | $2,679,559 | |
| Private capital raised | Form D · SEC | $5,100,000 | |
| Private capital raised | Form D · SEC | $9,101,001 | |
| Private capital raised | Form D · SEC | $1,665,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3302 | Hemp Synergistics LLC | — | $1.5M |
| 3303 | Stramsen Biotech, Inc. | — | $5.0M |
| 3304 | Syncromune, Inc. | — | $56M |
| 3305 | TuHURA Biosciences, Inc. | — | $21M |
| 3306 | Century Therapeutics | — | $160M |
| 3307 | SilverCeuticals Inc. | — | $5.0M |
| 3308 | ORF Biologics, Inc. | — | $2.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David BergmannDirector
- James BiancoDirector · Executive Officer
- Grahame CookDirector
- Dan DearbornExecutive Officer
- Daniel DearbornExecutive Officer
- Joseph ErricoDirector
- David LawmanDirector
- Michael LawmanDirector · Executive Officer
- Patricia LawmanDirector · Executive Officer
- Alan ListDirector
- James ManusoDirector
- James McNultyDirector
- George NgDirector
- Kiran PatelDirector
- Michael ShamblottExecutive Officer
- Scott SlaytonExecutive Officer
- Peter StaatsDirector
Patents
- Modified Mrna For Multicell Transformationapplication
- Materials And Methods For Treatment Of Melanomas And Other Cancersapplication
- Materials And Methods For Treatment Of Melanomas And Other Cancersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.